Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 AMPLIFICATION
(
ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- 141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/895
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/306
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Does Not Support
- Drug
- Cetuximab,Capecitabine,Oxaliplatin
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 24146218
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Capecitabine | Resitance or Non-Reponse | false |
| Cetuximab | Resitance or Non-Reponse | false |
| Oxaliplatin | Resitance or Non-Reponse | false |